On November 14 and 15, 2022, the National Cancer Policy Forum will host a public workshop that will examine the current challenges related to resistance to immune modulator therapies for cancer and ...
The gut mucosa is no longer viewed merely as a site of digestion and defense; it is now recognized as a central orchestrator ...
Preliminary monotherapy efficacy of novel immune checkpoint blockade GV20-0251 (anti-IGSF8) in advanced melanoma patients with primary resistance to anti-PD1. This is an ASCO Meeting Abstract from the ...
Failure-to-rescue after major complications in endometrial cancer: A National Inpatient analysis (NIS, 2016–2023). This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract ...
IO Biotech's vaccines activate T cells to modify the tumor microenvironment, targeting both cancer and immune-suppressive cells. The T-win technology combines IO102 and IO103, targeting IDO and PD-L1, ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
As people age, their immune system function declines. T cell populations become smaller and can’t react to pathogens as quickly, making individuals more susceptible to a variety of infections. To try ...
Within 24 hours of being born, Lewis Milne needed emergency surgery to remove a blockage in his small intestine. This type of blockage, called meconium ileus, can be the first sign of cystic fibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results